Literature DB >> 32556931

Antimicrobial Activity of Bacillus subtilis KATMIRA1933 and Bacillus amyloliquefaciens B-1895 Against Staphylococcus aureus Biofilms Isolated from Wound Infection.

Ammar Algburi1,2, Halah M Al-Hasani3, Thurya K Ismael4, Alyaa Abdelhameed3, Richard Weeks5, Aleksey M Ermakov6, Michael L Chikindas5,6.   

Abstract

Staphylococcal wound infections range from mild to severe with life-threatening complications. The challenge of controlling such infections is related to bacterial biofilm formation, which is a major factor contributing to antibiotic resistance and infection recurrence. In this study, four clinical isolates of staphylococci species; two isolates of methicillin-resistant Staphylococcus aureus (MRSA) and two methicillin-sensitive Staphylococcus aureus (MSSA) isolates. The identification of bacterial species based on cell morphology, initial biochemical tests, and the VITEK2 system were used to confirm the clinical microbiological diagnosis. Antibiotic sensitivity testing showed that the isolated staphylococci were highly resistant to the following antibiotics, amoxicillin, penicillin G, cefotaxime, and methicillin. Combinations of cefotaxime with the cell-free supernatants (CFS) of Bacillus subtilis KATMIRA1933 and Bacillus amyloliquefaciens B-1895, each one separately showed complementary activity against the tested staphylococci. The co-aggregation capability of the tested bacilli as beneficial bacteria against isolated staphylococci was also evaluated. The data showed a strong co-aggregation with scores (+ 3, + 4) which were reported between the bacilli strains and the isolated staphylococci. Furthermore, the CFS of bacilli strains showed an inhibitory effect against biofilm-associated MRSA and MSSA. These findings confirmed the ability of beneficial bacteria to compete with the pathogens at the site of colonization or for the source of nutrients and, eventually, lead to inhibition of the pathogens' capability of causing a wound infection. Such beneficial bacteria could play an important role in future pharmaceutical and industrial applications.

Entities:  

Keywords:  Bacillus probiotics; Biofilm inhibition; Co-aggregation; Methicillin resistance; Staphylococcus aureus

Mesh:

Substances:

Year:  2021        PMID: 32556931     DOI: 10.1007/s12602-020-09673-4

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  28 in total

Review 1.  The genetics of staphylococcal biofilm formation--will a greater understanding of pathogenesis lead to better management of device-related infection?

Authors:  F Fitzpatrick; H Humphreys; J P O'Gara
Journal:  Clin Microbiol Infect       Date:  2005-12       Impact factor: 8.067

Review 2.  Staphylococcus aureus infections.

Authors:  F D Lowy
Journal:  N Engl J Med       Date:  1998-08-20       Impact factor: 91.245

Review 3.  Control of Biofilm Formation: Antibiotics and Beyond.

Authors:  Ammar Algburi; Nicole Comito; Dimitri Kashtanov; Leon M T Dicks; Michael L Chikindas
Journal:  Appl Environ Microbiol       Date:  2017-01-17       Impact factor: 4.792

4.  DNA-protection and antioxidant properties of fermentates from Bacillus amyloliquefaciens B-1895 and Bacillus subtilis KATMIRA1933.

Authors:  E V Prazdnova; V A Chistyakov; M N Churilov; M S Mazanko; A B Bren; A Volski; M L Chikindas
Journal:  Lett Appl Microbiol       Date:  2015-11-02       Impact factor: 2.858

5.  Competition between methicillin-sensitive and -resistant Staphylococcus aureus in the anterior nares.

Authors:  M Dall'Antonia; P G Coen; M Wilks; A Whiley; M Millar
Journal:  J Hosp Infect       Date:  2005-09       Impact factor: 3.926

6.  The natural antimicrobial peptide subtilosin acts synergistically with glycerol monolaurate, lauric arginate, and ε-poly-L-lysine against bacterial vaginosis-associated pathogens but not human lactobacilli.

Authors:  Katia Sutyak Noll; Mark N Prichard; Arkady Khaykin; Patrick J Sinko; Michael L Chikindas
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

7.  Biofilm inhibitory and eradicating activity of wound care products against Staphylococcus aureus and Staphylococcus epidermidis biofilms in an in vitro chronic wound model.

Authors:  G Brackman; L De Meyer; H J Nelis; T Coenye
Journal:  J Appl Microbiol       Date:  2013-04-04       Impact factor: 3.772

8.  Isolation of the Bacillus subtilis antimicrobial peptide subtilosin from the dairy product-derived Bacillus amyloliquefaciens.

Authors:  K E Sutyak; R E Wirawan; A A Aroutcheva; M L Chikindas
Journal:  J Appl Microbiol       Date:  2007-11-01       Impact factor: 3.772

9.  A Framework to Reduce Infectious Disease Risk from Urban Poultry in the United States.

Authors:  Molly R Tobin; Jesse L Goldshear; Lance B Price; Jay P Graham; Jessica H Leibler
Journal:  Public Health Rep       Date:  2015 Jul-Aug       Impact factor: 2.792

10.  Methicillin-resistant Staphylococcus aureus in poultry.

Authors:  Davy Persoons; Sebastiaan Van Hoorebeke; Katleen Hermans; Patrick Butaye; Aart de Kruif; Freddy Haesebrouck; Jeroen Dewulf
Journal:  Emerg Infect Dis       Date:  2009-03       Impact factor: 6.883

View more
  3 in total

1.  Beneficial Effects of Spore-Forming Bacillus Probiotic Bacteria Isolated From Poultry Microbiota on Broilers' Health, Growth Performance, and Immune System.

Authors:  Maria S Mazanko; Igor V Popov; Evgeniya V Prazdnova; Aleksandr G Refeld; Anzhelica B Bren; Galina A Zelenkova; Vladimir A Chistyakov; Ammar Algburi; Richard M Weeks; Alexey M Ermakov; Michael L Chikindas
Journal:  Front Vet Sci       Date:  2022-05-31

2.  Probiotic Bacillus subtilis LF11 Protects Intestinal Epithelium Against Salmonella Infection.

Authors:  Rongling Zhang; Zhengguang Li; Xinyi Gu; Jiancun Zhao; Tingting Guo; Jian Kong
Journal:  Front Cell Infect Microbiol       Date:  2022-02-16       Impact factor: 5.293

3.  Antimicrobial and Anti-Biofilm Activity of Polymyxin E Alone and in Combination with Probiotic Strains of Bacillus subtilis KATMIRA1933 and Bacillus amyloliquefaciens B-1895 against Clinical Isolates of Selected Acinetobacter spp.: A Preliminary Study.

Authors:  Munaf Al-Dulaimi; Ammar Algburi; Alyaa Abdelhameed; Maria S Mazanko; Dmitry V Rudoy; Alexey M Ermakov; Michael L Chikindas
Journal:  Pathogens       Date:  2021-12-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.